One candidate, SLC7A21/xCT, was identified as a driver of cisplatin resistance in three BC cell lines, with siRNA knockdown exhibiting significant synergy with cisplatin compared to scrambled control (Figure 3C and D, and Supplementary S3A–C). Here, SLC7A11 is linked to breast cancer.